Jayud Global Logistics receives noncompliance letter from Nasdaq
Confident Investing Starts Here:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Why AppLovin (APP) Dipped More Than Broader Market Today
In the latest close session, AppLovin (APP) was down 2.95% at $379.17. This change lagged the S&P 500's daily loss of 1.6%. Elsewhere, the Dow saw a downswing of 1.23%, while the tech-heavy Nasdaq depreciated by 2.24%. Shares of the mobile app technology company have appreciated by 14.36% over the course of the past month, outperforming the Business Services sector's loss of 1.38%, and the S&P 500's gain of 2.25%. The investment community will be paying close attention to the earnings performance of AppLovin in its upcoming release. The company is slated to reveal its earnings on August 6, 2025. The company is expected to report EPS of $1.99, up 123.6% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $1.21 billion, showing a 12.34% escalation compared to the year-ago quarter. For the full year, the Zacks Consensus Estimates are projecting earnings of $8.39 per share and revenue of $5.51 billion, which would represent changes of +85.21% and +17.02%, respectively, from the prior year. Investors should also note any recent changes to analyst estimates for AppLovin. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.03% increase. AppLovin is currently a Zacks Rank #3 (Hold). In the context of valuation, AppLovin is at present trading with a Forward P/E ratio of 46.54. This indicates a premium in contrast to its industry's Forward P/E of 21.61. We can additionally observe that APP currently boasts a PEG ratio of 2.33. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. By the end of yesterday's trading, the Technology Services industry had an average PEG ratio of 1.79. The Technology Services industry is part of the Business Services sector. This industry, currently bearing a Zacks Industry Rank of 97, finds itself in the top 40% echelons of all 250+ industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize to follow all of these stock-moving metrics, and more, in the coming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AppLovin Corporation (APP) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
20 minutes ago
- Yahoo
Canopy Growth Corporation (CGC) Advances While Market Declines: Some Information for Investors
In the latest close session, Canopy Growth Corporation (CGC) was up +1.94% at $1.05. The stock outperformed the S&P 500, which registered a daily loss of 1.6%. Elsewhere, the Dow saw a downswing of 1.23%, while the tech-heavy Nasdaq depreciated by 2.24%. Coming into today, shares of the company had lost 19.53% in the past month. In that same time, the Medical sector lost 3.44%, while the S&P 500 gained 2.25%. Market participants will be closely following the financial results of Canopy Growth Corporation in its upcoming release. The company plans to announce its earnings on August 8, 2025. On that day, Canopy Growth Corporation is projected to report earnings of -$0.15 per share, which would represent year-over-year growth of 59.46%. Alongside, our most recent consensus estimate is anticipating revenue of $47.91 million, indicating a 0.99% downward movement from the same quarter last year. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.46 per share and revenue of $198.45 million. These totals would mark changes of +84.56% and +2.66%, respectively, from last year. Investors might also notice recent changes to analyst estimates for Canopy Growth Corporation. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 5.38% lower. Canopy Growth Corporation currently has a Zacks Rank of #5 (Strong Sell). The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 183, which puts it in the bottom 26% of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Don't forget to use to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Canopy Growth Corporation (CGC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
20 minutes ago
- Yahoo
Why Fulgent Genetics Stock Was Crushing It on Friday
Key Points The company posted an unexpected profit in its latest reported quarter. That was accompanied by a double-digit improvement in revenue. 10 stocks we like better than Fulgent Genetics › Friday's stock market was generally a gloomy place, but apparently someone forgot to tell Fulgent Genetics (NASDAQ: FLGT). The company's shares were soaring in late-session action, with a very healthy rise of more than 8%. At that point, the bellwether S&P 500 index was mired in a funk with a nearly 2% decline. Fulgent's latest earnings release was a major reason for this dichotomy. A surprise on the bottom line That morning, before market open, Fulgent unveiled its second-quarter results. The genetic testing specialist posted revenue just shy of $82 million, a figure that was more than 15% higher year over year. Non-GAAP (adjusted) net income went the opposite way with a steep (56%) decrease to slightly over $2 million ($0.07 per share). Yet the analysts tracking the stock were, as a group, expecting worse. In fact, they were modeling an adjusted bottom-line loss of $0.18 per share on revenue of only $76 million. In its earnings release, Fulgent credited diversification for the better-than-expected results. It quoted CEO Ming Hsieh as saying that throughout the first half of this year, "we made good progress in growing revenue for our laboratory services business and in advancing our clinical trials for the therapeutic development business." The kind of adjustment investors love Fulgent also raised its revenue and adjusted bottom-line guidance for full-year 2025. Management now anticipates the company will book "core" revenue -- that is, revenue minus the take from COVID testing products and services -- of roughly $320 million and an adjusted net loss of $0.35 per share. Those numbers top the average pundit projections of $0.55 for net loss and under $311 million for revenue. Do the experts think Fulgent Genetics is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Fulgent Genetics make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,036% vs. just 181% for the S&P — that is beating the market by 855.09%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Fulgent Genetics. The Motley Fool has a disclosure policy. Why Fulgent Genetics Stock Was Crushing It on Friday was originally published by The Motley Fool Sign in to access your portfolio
